<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the adult with chronic diarrhea in resource-abundant settings</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the adult with chronic diarrhea in resource-abundant settings</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the adult with chronic diarrhea in resource-abundant settings</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A L Bonis, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diarrhea is a common manifestation of gastrointestinal disease and is a leading cause of health care utilization [<a href="#rid1">1,2</a>]. Optimal strategies for the evaluation of patients with chronic diarrhea have not been established. The selection of specific tests, timing of referral, and the extent to which testing should be performed depend upon an appraisal of the likelihood of a specific diagnosis, the availability of treatment, the severity of symptoms, patient preference, and comorbidities. However, a specific diagnosis can be achieved in more than 90 percent of patients.</p><p>This topic review will provide an overview of the evaluation and treatment of chronic diarrhea. Individual disorders associated with chronic diarrhea and an approach to patients with acute diarrhea are presented separately. (See  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a> and  <a class="medical medical_review" href="/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/3728.html" rel="external">"Evaluation of the patient with HIV and diarrhea"</a> and  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a>.)</p><p class="headingAnchor" id="H1756319094"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Chronic diarrhea is defined as a persistent alteration of stool consistency from the norm with loose stools (consistency between types 5 and 7 on the Bristol stool chart) and increased stool frequency of greater than three stools daily of at least four weeks' duration [<a href="#rid3">3-7</a>].</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of chronic diarrhea in the general population in resource-abundant settings has not been well established. The variable rates observed in several studies reflect differences in study design, definitions, and characteristics of populations that have been sampled. Based upon a commonly used definition (ie, the presence of excessive stool frequency) a reasonable approximation is that chronic diarrhea affects approximately 3 to 7 percent of the population [<a href="#rid4">4,8,9</a>]. Chronic diarrhea can decrease quality of life. However, accurate assessment of the degree to which this occurs has not been established. Direct and indirect costs of chronic diarrhea in the United States are estimated to be at least $524 million per year and $136 million per year, respectively [<a href="#rid10">10-12</a>].</p><p class="headingAnchor" id="H3817285327"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The principal causes of diarrhea vary based upon the socioeconomic status of the population. In resource-abundant settings, common causes are irritable bowel syndrome (IBS), inflammatory bowel disease, malabsorption syndromes (such as lactose intolerance and celiac disease), and chronic infections (particularly in patients who are immunocompromised)  (<a class="graphic graphic_table graphicRef120862" href="/d/graphic/120862.html" rel="external">table 1</a>). In resource-limited settings, chronic diarrhea is frequently caused by chronic bacterial, mycobacterial, and parasitic infections, although functional disorders, malabsorption, and inflammatory bowel disease are also common.</p><p>The following sections highlight important distinguishing clinical features of some the most prevalent disorders associated with chronic diarrhea. Other less prevalent causes are listed in the table  (<a class="graphic graphic_table graphicRef120862" href="/d/graphic/120862.html" rel="external">table 1</a>). Detailed discussions on these and other disorders associated with chronic diarrhea are presented in the corresponding topic reviews.</p><p class="headingAnchor" id="H1947184601"><span class="h2">Functional disorders</span><span class="headingEndMark"> — </span>Patients with IBS complain of cramping lower-quadrant pain associated with altered bowel habits (diarrhea, constipation, alternating diarrhea and constipation). Diarrhea is usually characterized as frequent loose stools of small to moderate volume. Stools generally occur during waking hours, most often in the morning or after meals. Some bowel movements are preceded by extreme urgency and may be followed by a feeling of incomplete evacuation or tenesmus. Incontinence of liquid stool may occur during periods of disease activity. Approximately one-half of all patients with IBS complain of mucus discharge with stools. Symptoms of IBS often correlate with episodes of psychologic stress. Thus, patients often seek medical help for their chronic symptoms during such periods. Patients usually experience the onset of symptoms as young adults, but the prevalence is similar in older adults. Post-infectious IBS can occur following recovery from <em>Clostridioides difficile</em> and other bacterial infections. (See  <a class="medical medical_review" href="/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults"</a> and  <a class="medical medical_review" href="/d/html/2629.html" rel="external">"Pathophysiology of irritable bowel syndrome"</a>.)</p><p>A number of related functional bowel disorders have also been described to include functional diarrhea, IBS with predominant diarrhea, and IBS with mixed bowel habits [<a href="#rid13">13</a>]. These disorders are considered to represent a continuum, rather than being independent entities, according to a consensus of experts [<a href="#rid14">14,15</a>]. Functional diarrhea is characterized by recurrent passage of loose or watery stools. Patients with functional diarrhea should not meet criteria for IBS. Patients with functional diarrhea may have abdominal pain and/or bloating, but unlike IBS, these are not predominant symptoms.</p><p class="headingAnchor" id="H4204951454"><span class="h2">Organic disorders</span><span class="headingEndMark"> — </span>Organic disorders are conditions that are associated with physiologic, structural, or biochemical abnormalities. Organic disorders are more likely in adults with "alarm" features  (<a class="graphic graphic_table graphicRef120912" href="/d/graphic/120912.html" rel="external">table 2</a>). (See <a class="local">'Evaluation for alarm features'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h3">Inflammatory bowel disease</span><span class="headingEndMark"> — </span>Inflammatory bowel disease (IBD) primarily refers to ulcerative colitis and Crohn disease, although other intestinal disorders are also associated with intestinal inflammation. Most cases of ulcerative colitis and Crohn disease have their onset between ages 15 and 40. Many studies suggest a bimodal age distribution for both disorders with a second peak between age 50 and 80. IBD tends to run in families and is more common in individuals with Jewish ancestry. (See  <a class="medical medical_review" href="/d/html/4066.html" rel="external">"Definitions, epidemiology, and risk factors for inflammatory bowel disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crohn disease</strong> – Crohn disease may involve the entire gastrointestinal tract from mouth to perianal area. Diarrhea, abdominal pain, weight loss, and fever are the typical clinical manifestations for most patients with ileitis, ileocolitis, or Crohn colitis. Patients can have symptoms for many years prior to diagnosis. Although occult GI blood loss is common in Crohn disease, gross bleeding is much less frequent than in ulcerative colitis (except for some patients with Crohn colitis). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ulcerative colitis</strong> – Patients with ulcerative colitis may present in a variable manner. The history is typically one of the gradual onset of symptoms, sometimes preceded by a self-limited episode of rectal bleeding that occurred weeks or months earlier. The initial episode is limited to the rectum or distal colon in one-third of patients, to the left colon up to the splenic flexure in one-third, and most of the remaining patients have pancolitis. Less than 10 percent present with fulminant disease. (See  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Microscopic colitis</span><span class="headingEndMark"> — </span>Microscopic colitis usually occurs in middle-aged and older adults, but it can also affect children. Microscopic colitis has two main histologic subtypes (lymphocytic colitis and collagenous colitis). Both subtypes have a similar clinical presentation. Patients with microscopic colitis usually have between four and nine watery stools per day, but in rare cases, bowel movements can exceed 1.5 or up to 2 liters per day. The clinical course is mainly intermittent. (See  <a class="medical medical_review" href="/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Clinical manifestations'</a>.)</p><p>Colonoscopy usually reveals macroscopically normal colonic mucosa, although slight edema, erythema, and friability may be seen. Although specimens obtained by flexible sigmoidoscopy are frequently sufficient to establish the diagnosis, the severity of histologic changes declines from the proximal to the distal colon; thus, colonoscopic biopsies should be obtained from the entire colon. (See  <a class="medical medical_review" href="/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Diagnostic approach'</a> and <a class="local">'Endoscopic evaluation'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h3">Malabsorption syndromes</span><span class="headingEndMark"> — </span>The classic manifestations of malabsorption are pale, greasy, voluminous, foul-smelling stools, and weight loss despite adequate food intake. However, this spectrum of findings is relatively uncommon, even in generalized mucosal disease. The majority of patients with malabsorption have relatively mild gastrointestinal symptoms, which often mimic more common disorders such as IBS. In some cases, flatulence, abdominal distension, and borborygmi may be the only complaints suggesting malabsorption; other patients may be asymptomatic. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a>.)</p><p>The clinical and laboratory features of malabsorption depend upon the cause and severity of the disease  (<a class="graphic graphic_table graphicRef76166" href="/d/graphic/76166.html" rel="external">table 3</a>). As an example, isolated forms of malabsorption may present solely with symptoms that are attributable to the particular nutrient in question  (<a class="graphic graphic_table graphicRef53852" href="/d/graphic/53852.html" rel="external">table 4</a>). Iron deficiency anemia may be the only clue to the presence of celiac disease. (See  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a>.)</p><p>Relatively common disorders associated with malabsorption include:</p><p class="bulletIndent1"><span class="glyph">●</span>Lactose intolerance (see  <a class="medical medical_review" href="/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic pancreatitis (see  <a class="medical medical_review" href="/d/html/5649.html" rel="external">"Chronic pancreatitis: Clinical manifestations and diagnosis in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Celiac disease (see  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial overgrowth of the small intestine (see  <a class="medical medical_review" href="/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="headingAnchor" id="H16433027"><span class="h3">Post-cholecystectomy diarrhea</span><span class="headingEndMark"> — </span>The incidence of diarrhea following cholecystectomy has ranged from as low as 2 percent to as high as 50 percent in various reports reflecting the various populations, differences in study design, and the degree to which diarrhea was sought [<a href="#rid16">16-18</a>]. In many cases, the diarrhea will resolve or significantly improve over the course of weeks to months [<a href="#rid19">19</a>]. The diarrhea is related to excessive bile acids entering the colon [<a href="#rid20">20,21</a>]. In the absence of a gallbladder, bile drains directly and more continuously into the small bowel, which may overcome the terminal ileum's reabsorptive capacity. The increased bile acids in the colon lead to diarrhea (cholerheic diarrhea) [<a href="#rid22">22</a>]. Patients often respond to treatment with bile-acid binding resins such as <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> or <a class="drug drug_general" data-topicid="9294" href="/d/drug information/9294.html" rel="external">colestipol</a> [<a href="#rid23">23</a>]. (See <a class="local">'Empiric therapy in selected patients'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h3">Chronic infections</span><span class="headingEndMark"> — </span>Some persisting infections (eg, <em>C. difficile</em>, <em>Aeromonas</em>, <em>Plesiomonas</em>, <em>Campylobacter</em>, <em>Giardia</em>, <em>Amebae</em>, <em>Cryptosporidium</em>, Whipple's disease, and <em>Cyclospora</em>) can be associated with chronic diarrhea [<a href="#rid24">24</a>]. Microsporidium should be a consideration in immunocompromised patients with persistent diarrhea. (See appropriate topic reviews).</p><p>Several other causes of chronic diarrhea caused by, or resulting from a presumed infection have been described:</p><p class="bulletIndent1"><span class="glyph">●</span>An epidemic form of secretory diarrhea (Brainerd diarrhea) associated with patchy lymphocytic colonic inflammation can cause symptoms that persist for up to three years [<a href="#rid25">25-30</a>]. Risk factors include consumption of contaminated water and unpasteurized milk. An infectious agent is suspected but has not been identified.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The development of post-infectious irritable bowel syndrome has also been described in up to 30 percent of patients following documented acute bacterial enteric infections. (See  <a class="medical medical_review" href="/d/html/2629.html" rel="external">"Pathophysiology of irritable bowel syndrome"</a> and <a class="local">'Functional disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is possible that some patients with chronic diarrhea may have an infectious cause that may not be easily demonstrable. A case report described a woman with severe, debilitating diarrhea that was ultimately found to be due to <em>Stenotrophomonas maltophilia</em>, a Gram-negative rod that was only identifiable using molecular genetic techniques [<a href="#rid31">31</a>]. Further studies using such techniques will help determine whether other infectious agents can be implicated in chronic diarrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic diarrhea due to <em>Candida albicans</em> infection has been described in case reports [<a href="#rid32">32</a>]. Most patients had received immunosuppression (in some cases with antibiotics), were malnourished, or had an immune disorder [<a href="#rid32">32</a>]. Diagnosis was established by detection of large numbers of <em>Candida</em> in small bowel aspirates and stool specimens, and response to antifungal therapy. The presence of <em>Candida</em> in stool specimens has also been described in asymptomatic individuals, and thus, the clinical context is important in considering the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic infection with <em>Blastocystis hominis</em>, an anaerobic protozoan parasite, has been implicated as a cause of chronic diarrhea in some reports. (See  <a class="medical medical_review" href="/d/html/5672.html" rel="external">"Blastocystis species"</a>.)</p><p></p><p class="headingAnchor" id="H1494761525"><span class="h3">Medications</span><span class="headingEndMark"> — </span>Many drugs can cause diarrhea through a variety of mechanisms [<a href="#rid33">33-37</a>]. It can be challenging to identify the agent causing drug-induced diarrhea, particularly in patients taking multiple medications  (<a class="graphic graphic_table graphicRef71449" href="/d/graphic/71449.html" rel="external">table 5</a>). The clinical setting and timing of the onset of symptoms relative to when the medications were started can be helpful.</p><p class="headingAnchor" id="H1206056822"><span class="h1">INDICATIONS FOR REFERRAL TO A GASTROENTEROLOGIST</span><span class="headingEndMark"> — </span>The need for gastroenterology evaluation and timing of referral depend upon the severity of symptoms, the diagnoses being considered, and the presence of alarm features  (<a class="graphic graphic_table graphicRef120912" href="/d/graphic/120912.html" rel="external">table 2</a>). (See <a class="local">'Evaluation for alarm features'</a> below and <a class="local">'Establishing a diagnosis'</a> below.)</p><p>Indications for referral include anyone of the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Alarm features </p><p class="bulletIndent1"><span class="glyph">●</span>Severe diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected inflammatory bowel disease (see <a class="local">'Inflammatory bowel disease'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Inconclusive diagnosis after initial evaluation (see <a class="local">'Initial evaluation'</a> below and <a class="local">'Establishing a diagnosis'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to respond to empiric therapy (see <a class="local">'Empiric therapy in selected patients'</a> below)</p><p></p><p>Referral to a gastroenterologist may also be appropriate in patients who require long-term management for the underlying cause (eg, inflammatory bowel disease, chronic pancreatitis). </p><p class="headingAnchor" id="H14"><span class="h1">INITIAL EVALUATION</span></p><p class="headingAnchor" id="H2639979478"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The initial evaluation of patient with chronic diarrhea includes history, physical examination, and laboratory testing to determine whether the patient has any alarm findings which help to distinguish organic from functional diarrhea and characterizing the diarrhea in order to direct the need for additional evaluation  (<a class="graphic graphic_algorithm graphicRef120910" data-inline-graphics="120910" href="/d/graphic/120910.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H110644121"><span class="h3">Evaluation for alarm features</span><span class="headingEndMark"> — </span>Alarm features in patients with chronic diarrhea may be suggestive of an underlying organic etiology  (<a class="graphic graphic_table graphicRef120912" href="/d/graphic/120912.html" rel="external">table 2</a>). These features include the following (see <a class="local">'Organic disorders'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Age of onset after age 50 years</p><p class="bulletIndent1"><span class="glyph">●</span>Rectal bleeding or melena [<a href="#rid6">6</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Nocturnal pain or diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained weight loss, fever, or other systemic symptoms </p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory abnormalities (iron deficiency anemia, elevated C-reactive protein or fecal calprotectin)</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of inflammatory bowel disease (IBD) or colorectal cancer</p><p></p><p class="headingAnchor" id="H970319415"><span class="h3">Characterizing the diarrhea type</span><span class="headingEndMark"> — </span>Information other than alarm features obtained in the initial evaluation helps to distinguish among organic etiologies. Characterizing the diarrhea (infectious, inflammatory, osmotic, secretory) is a useful way to guide evaluation and the diagnosis can then be confirmed by focused testing  (<a class="graphic graphic_table graphicRef120864" data-inline-graphics="120864" href="/d/graphic/120864.html" rel="external">table 6</a>). The distinction between types of diarrhea can often be made based upon the medical history but in other cases may require additional laboratory evaluation. (See <a class="local">'Laboratory evaluation'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Watery diarrhea</strong> – The water content of chronic diarrhea can be caused by secretory or osmotic processes, or a combination of the two. These categories are useful to narrow the diagnostic possibilities. However, the clinical utility of these categories and their diagnostic markers is limited because some diarrheal diseases involve a combination of both processes. If needed, it is possible to distinguish between these processes by measurement of fecal electrolytes, pH, reducing substances, and calculation of the osmotic gap. (See <a class="local">'Laboratory evaluation'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secretory </strong>– Secretory diarrhea<strong> </strong>is usually associated with large volumes of watery stools and persists during fasting. Consequently, it is helpful to assess the effects of fasting on stool output. Pure secretory diarrheas are uncommon, but can occur in the setting of certain enteric infections. Secretory diarrhea occurs in 80 percent of patients with carcinoid syndrome and is often the most debilitating component of the syndrome. Stools may vary from few to more than 30 per day, are typically watery and nonbloody, and can be explosive and accompanied by abdominal cramping. The abdominal cramps may be a consequence of mesenteric fibrosis or intestinal blockage by the primary tumor. The diarrhea is usually unrelated to flushing episodes. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Osmotic </strong>– Osmotic (or "substrate-induced" or "diet-related") diarrhea typically is less voluminous than secretory diarrhea (eg, &lt;200 mL per day), and improves or resolves during 12- to 24-hours of fasting. The presence of reducing substances or low fecal pH (ie, pH &lt;6) suggest carbohydrate malabsorption. Osmotic diarrheas are characterized by relatively low sodium concentration (&lt;70 mEq/L) and a high osmotic gap (&gt;75 mOsm/kg) but testing stool osmolality is not routinely required. (See <a class="local">'Laboratory evaluation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fatty diarrhea </strong>– Malabsorption is often accompanied by steatorrhea and the passage of bulky malodorous pale stools. However, milder forms of malabsorption may not result in any reported stool abnormality. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory diarrhea </strong>– Inflammatory forms of diarrhea typically present with liquid loose stools with blood. Elevation in fecal calprotectin (a protein found in neutrophil granulocytes) indicates an inflammatory diarrhea. The presence of occult blood also raises this possibility but is less specific. (See <a class="local">'General laboratory tests'</a> below.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">History</span><span class="headingEndMark"> — </span>The initial evaluation of patients who present to medical care with chronic diarrhea should include a careful history to determine the duration of symptoms, the frequency and characteristics of the stool, and the presence of associated symptoms. Fecal incontinence is frequently misinterpreted as diarrhea. A thorough medical history can guide appropriate evaluation. Important components of the history include the following  (<a class="graphic graphic_table graphicRef80934" href="/d/graphic/80934.html" rel="external">table 7</a>):</p><p class="headingAnchor" id="H2073921848"><span class="h3">Symptom characteristics</span></p><p class="bulletIndent1"><span class="glyph">●</span>A clear understanding of what led the patient to complain of diarrhea (eg, consistency or frequency of stools, the presence of urgency or fecal incontinence).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stool characteristics (eg, greasy stools that float and are malodorous may suggest fat malabsorption, while the presence of visible blood may suggest an inflammatory cause of diarrhea). Patients with carbohydrate malabsorption (eg, lactose malabsorption) may be present with watery diarrhea, excess flatus, and bloating. (See <a class="local">'Characterizing the diarrhea type'</a> above and <a class="local">'Malabsorption syndromes'</a> above and  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of symptoms, nature of onset (sudden or gradual).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Occurrence of diarrhea during fasting or at night suggests a secretory or inflammatory diarrhea. (See <a class="local">'Characterizing the diarrhea type'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The volume of the diarrhea (eg, voluminous watery diarrhea is more likely to be due to a disorder in the small bowel, while small-volume frequent diarrhea is more likely to be due to disorders of the colon). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of bloody diarrhea favors a colonic versus small bowel disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of weight loss and other systemic symptoms may indicate IBD (eg, fevers, joint pains, mouth ulcers, eye redness).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Association of stress and depression with onset and severity of the diarrhea suggests a functional disorder such as irritable bowel syndrome. Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain and altered bowel habits. Symptoms of IBS include diarrhea, constipation, alternating diarrhea and constipation, or normal bowel habits alternating with either diarrhea and/or constipation. (See <a class="local">'Functional disorders'</a> above and  <a class="medical medical_review" href="/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults", section on 'History and physical examination'</a>.)</p><p></p><p class="headingAnchor" id="H2304878123"><span class="h3">Risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span>Travel to a resource-limited setting increases the risk of bacterial diarrhea and also informs the risk of certain parasitic infections. (See <a class="local">'Characterizing the diarrhea type'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of <em>Clostridiodes (formerly Clostridium difficile)</em> infection and risk factors for <em>C. difficile. </em>(See  <a class="medical medical_review" href="/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All medications (including over-the-counter drugs and supplements)  (<a class="graphic graphic_table graphicRef71449" href="/d/graphic/71449.html" rel="external">table 5</a>) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dietary history should include possible use of sorbitol-containing products, food additives including fructose and other fermentable oligo-, di-, mono-saccharides and polyols, alcohol and association of symptoms with specific food ingestion (eg, dairy products or potential food allergens)  (<a class="graphic graphic_table graphicRef90186" href="/d/graphic/90186.html" rel="external">table 8</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical history:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A history of or risk factors for sexually transmitted diseases. As examples, Neisseria gonorrhoeae and herpes simplex virus are associated with proctitis. HIV infection is associated with diarrhea due to infectious agents but may also be due to infiltrative diseases, such as lymphoma or Kaposi's sarcoma or antiretroviral medication use. (See  <a class="medical medical_review" href="/d/html/3728.html" rel="external">"Evaluation of the patient with HIV and diarrhea"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A history of recurrent bacterial infections (eg, sinusitis, pneumonia), which may indicate a primary immunoglobulin deficiency. (See  <a class="medical medical_review" href="/d/html/3928.html" rel="external">"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A history of chronic diseases associated with amyloidosis (eg, chronic degenerative arthropathies, particularly rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis and plasma cell dyscrasias). (See  <a class="medical medical_review" href="/d/html/2642.html" rel="external">"Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management", section on 'Gastrointestinal tract amyloidosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with a history of an allogeneic hematopoietic cell transplant, graft versus host disease and among recipients of umbilical cord blood, cord colitis syndrome can cause diarrhea. Radiation enteritis can also cause chronic diarrhea, and in some cases can occur several years after treatment. (See  <a class="medical medical_review" href="/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Gastrointestinal tract'</a> and  <a class="medical medical_review" href="/d/html/7054.html" rel="external">"Overview of gastrointestinal toxicity of radiation therapy", section on 'Enteritis'</a> and  <a class="medical medical_review" href="/d/html/4057.html" rel="external">"Diagnosis and management of chronic radiation enteritis", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation", section on 'Cord colitis syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior gastrointestinal surgeries can lead to diarrhea due to intentional or inadvertent vagotomy, small intestinal bacterial overgrowth, and based on the length of small bowel resection, bile acid malabsorption, or short bowel syndrome. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a> and  <a class="medical medical_review" href="/d/html/4782.html" rel="external">"Overview of the treatment of malabsorption in adults"</a> and  <a class="medical medical_review" href="/d/html/4770.html" rel="external">"Pathophysiology of short bowel syndrome", section on 'Initial determinants of intestinal function'</a> and  <a class="medical medical_review" href="/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diarrhea in patients with diabetes may also be due to visceral autonomic neuropathy, pancreatic exocrine insufficiency, bacterial overgrowth, or fecal incontinence (which may be confused with diarrhea). (See  <a class="medical medical_review" href="/d/html/2643.html" rel="external">"Diabetic autonomic neuropathy of the gastrointestinal tract"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family history of colorectal cancer, celiac disease and inflammatory bowel disease (IBD)are associated with an increased risk of these disorders. (See  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Individuals with high celiac disease probability'</a> and  <a class="medical medical_review" href="/d/html/4062.html" rel="external">"Genetic factors in inflammatory bowel disease"</a>.)</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>A comprehensive physical examination should be performed that includes a dermatologic examination and rectal examination. Physical examination rarely provides a specific diagnosis. However, a number of findings can provide clues  (<a class="graphic graphic_table graphicRef80934" href="/d/graphic/80934.html" rel="external">table 7</a>).</p><p class="headingAnchor" id="H2787993826"><span class="h2">General laboratory tests</span><span class="headingEndMark"> — </span>We suggest the following initial tests for most patients with chronic diarrhea  (<a class="graphic graphic_table graphicRef80934" href="/d/graphic/80934.html" rel="external">table 7</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count and differential. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid stimulating hormone and free thyroxine (T4) to identify patients with hyperthyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Celiac serologies (see  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Overview'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes in patients with severe diarrhea, or concern for dehydration or electrolyte abnormalities. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stool occult blood – Gross or occult gastrointestinal bleeding is suggestive of organic disease (eg, chronic infection or IBD). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stool test for giardia – Giardia stool antigen and nucleic acid detection tests are more sensitive for the diagnosis of giardiasis as compared to stool microscopy. (See  <a class="medical medical_review" href="/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fecal calprotectin or fecal lactoferrin – Fecal calprotectin levels are increased in intestinal inflammation and may be useful for distinguishing inflammatory from noninflammatory causes of chronic diarrhea [<a href="#rid38">38,39</a>]. Calprotectin is a zinc and calcium binding protein that is derived mostly from neutrophils and monocytes. It can be detected in tissue samples, body fluids, and stools, making it a potentially valuable marker of neutrophil activity [<a href="#rid40">40</a>]. The fecal lactoferrin test is an agglutination assay that is a marker for fecal leukocytes [<a href="#rid41">41</a>]. </p><p></p><p class="bulletIndent1">If fecal calprotectin and fecal lactoferrin are normal, a diagnosis of IBD is unlikely. If fecal calprotectin or fecal lactoferrin levels are above the reference range, we proceed with ileocolonoscopy and biopsy to confirm the diagnosis of IBD. (See <a class="local">'Patients with alarm features'</a> below and <a class="local">'Inflammatory bowel disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C-reactive protein – C-reactive protein levels have limited utility in differentiating IBS and IBD and should be performed in the evaluation of patients with chronic diarrhea if fecal calprotectin and fecal lactoferrin cannot be performed [<a href="#rid42">42</a>].</p><p></p><p>Additional laboratory evaluation may be warranted if specific organic conditions are suspected:</p><p class="headingAnchor" id="H1546640624"><span class="h2">Other tests</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stool microbiologic evaluation </strong>– Patients with recent antibiotic therapy or suspected Clostridioides difficile <em>infection should undergo testing for </em>C. difficile associated diarrhea. (See  <a class="medical medical_review" href="/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis", section on 'When to suspect and test for C. difficile infection'</a>.)</p><p></p><p class="bulletIndent1">Additional testing may also be indicated based on other risk factors for infectious diarrhea. Persistent diarrhea following travel to certain locations, such as Russia, Nepal, or mountainous regions, is associated with <em>Giardia</em>, <em>Cryptosporidium</em>, or <em>Cyclospora</em>. Persistent diarrhea with exposure to infants in daycare centers has been associated with <em>Giardia</em> and <em>Cryptosporidium</em>. Microsporidium should be a consideration in immunocompromised patients with persistent diarrhea. (See  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Persistent diarrhea'</a> and  <a class="medical medical_review" href="/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5733.html" rel="external">"Cryptosporidiosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5724.html" rel="external">"Cyclospora infection", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5731.html" rel="external">"Microsporidiosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fecal leukocytes </strong>– Fecal leukocyte evaluation is not an accurate test for inflammatory diarrhea [<a href="#rid43">43</a>]. A number of studies have evaluated the accuracy of fecal leukocytes alone or in combination with occult blood testing. The ability of these tests to predict the presence of an inflammatory diarrhea has varied greatly, with reports of sensitivity and specificity ranging from 20 to 90 percent [<a href="#rid44">44-47</a>]. A meta-analysis of diagnostic test accuracy estimated that at a peak sensitivity of 70 percent, the specificity of fecal leukocytes was only 50 percent [<a href="#rid47">47</a>]. </p><p></p><p class="headingAnchor" id="H3304099162"><span class="h1">ESTABLISHING A DIAGNOSIS</span></p><p class="headingAnchor" id="H1963843810"><span class="h2">Patients with alarm features</span><span class="headingEndMark"> — </span>Patients with alarm findings require endoscopic evaluation for organic disorders. Patients with abdominal pain as a major symptom in addition to chronic diarrhea often require abdominal imaging  (<a class="graphic graphic_table graphicRef120912" href="/d/graphic/120912.html" rel="external">table 2</a>). (See <a class="local">'Imaging in selected patients'</a> below and <a class="local">'Endoscopic evaluation'</a> below.)</p><p>If an etiology is established, patients should be managed based on the underlying cause. If an etiology is not identified, additional evaluation should be guided by the initial evaluation similar to patients without alarm features. (See <a class="local">'Treatment of the underlying etiology'</a> below and <a class="local">'Patients without alarm features'</a> below.)</p><p class="headingAnchor" id="H652641302"><span class="h2">Patients without alarm features</span></p><p class="headingAnchor" id="H2596195009"><span class="h3">Specific diagnosis suspected</span><span class="headingEndMark"> — </span>If the initial evaluation points toward a specific diagnosis or type of diarrhea, further testing should be directed toward confirming the diagnosis. As examples, upper endoscopy with duodenal biopsies can establish the diagnosis of celiac disease in a patient with positive celiac serologies; breath test for bacterial overgrowth in a patient with risk factors; in a patient with suspected inflammatory bowel disease (IBD) due to a family history of IBD, the diagnosis can usually be established by colonoscopy. (See <a class="local">'Initial evaluation'</a> above and  <a class="medical medical_review" href="/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Etiology and risk factors'</a>.)</p><p>Further testing in patients with osmotic diarrhea may be unnecessary if the osmotic agent can be identified based upon the history. An example is inadvertent ingestion of <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> (such as in sugar substitutes) or lactose in patients who have lactose intolerance. Temporary avoidance of lactose-containing foods can help establish the diagnosis of lactose intolerance in patients who were unaware of the diagnosis. (See  <a class="medical medical_review" href="/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management", section on 'Management'</a>.)</p><p>In other cases, empiric therapy may be indicated (eg, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> for bile acid malabsorption in a patient with a history of ileal resection). (See <a class="local">'Empiric therapy in selected patients'</a> below.)</p><p class="headingAnchor" id="H3180681255"><span class="h3">Functional bowel disease suspected</span><span class="headingEndMark"> — </span>A clinical diagnosis of irritable bowel syndrome (IBS) or functional diarrhea requires the fulfillment of symptom-based diagnostic criteria and a limited initial evaluation to exclude underlying organic disease. In patients with IBS, these include presence of recurrent abdominal pain at least three days per month in the last three months, associated with a change in stool frequency or form, and improvement with defecation. Functional diarrhea is defined as similar stool changes without prominent pain. (See <a class="local">'Initial evaluation'</a> above and <a class="local">'Functional disorders'</a> above and  <a class="medical medical_review" href="/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults", section on 'Diagnosis'</a>.)</p><p>However, the presence of persistent symptoms despite treatment, atypical symptoms (eg, older age of onset), or progressive symptoms require additional evaluation for alternative etiologies. (See <a class="local">'Additional testing in specific circumstances'</a> below.)</p><p class="headingAnchor" id="H1871190626"><span class="h3">Unclear diagnosis after initial evaluation</span><span class="headingEndMark"> — </span>If the initial evaluation does not point toward a specific diagnosis, we perform additional testing. (See <a class="local">'Overview'</a> above and <a class="local">'Additional testing in specific circumstances'</a> below.)</p><p class="headingAnchor" id="H2225875083"><span class="h1">ADDITIONAL TESTING IN SPECIFIC CIRCUMSTANCES</span><span class="headingEndMark"> — </span>For patients with persistent diarrhea with no clear etiology after initial evaluation or diarrhea that does not respond to initial treatment, we perform additional testing to determine the underlying etiology. The order and extent of testing should be individualized based on the clinical presentation and results of initial evaluation. (See <a class="local">'Initial evaluation'</a> above.)</p><p class="headingAnchor" id="H1390379872"><span class="h2">Laboratory evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood tests for malabsorption</strong> – An initial screen for nutritional deficits can provide indirect evidence of malabsorption. This includes a complete blood count, red cell folate and serum iron, total iron binding capacity, vitamin B12, calcium, magnesium, albumin, carotene, and 25-hydroxyvitamin D. Blood tests can provide supportive evidence of malabsorption. Clinical or laboratory features suggesting malabsorption should prompt a specific evaluation  (<a class="graphic graphic_table graphicRef76166" href="/d/graphic/76166.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef53852" href="/d/graphic/53852.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stool tests </strong>– Work-up for patients with persistent diarrhea should include evaluation for <em>C. difficile</em> and parasitic infections (eg, <em>Giardia</em>, <em>Cryptosporidium</em>, <em>Cyclospora</em>, <em>E. histolytica</em>), if not already performed. Microsporidium should be a consideration in immunocompromised patients with persistent diarrhea. (See <a class="local">'General laboratory tests'</a> above and  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Persistent diarrhea'</a> and  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Immunocompromised patients'</a>.)</p><p></p><p class="headingAnchor" id="H797268502"><span class="h2">Endoscopic evaluation</span><span class="headingEndMark"> — </span>We generally perform colonoscopy and obtain mucosal biopsies in patients with chronic diarrhea, if not previously performed. Colonoscopy has the advantage of allowing evaluation of the terminal ileum and sampling of the right and left colon. Flexible sigmoidoscopy (to 60 cm) is less expensive, is associated with fewer risks as compared with colonoscopy and may be appropriate for selected patients [<a href="#rid48">48-51</a>]. However, colonoscopy should be performed in patients with iron deficiency anemia, those in whom inspection of the terminal ileum is needed (eg, to exclude Crohn disease), patients who require age appropriate screening for colorectal cancer, and those with suspected microscopic colitis. (See  <a class="medical medical_review" href="/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Endoscopy and biopsy'</a>.)</p><p>In patients with positive serologic testing for celiac disease and in patients at increased risk for celiac disease (regardless of celiac specific serology results), an upper endoscopy with small bowel biopsy should be performed. (See  <a class="medical medical_review" href="/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Overview'</a>.)</p><p class="headingAnchor" id="H2007327487"><span class="h2">Imaging in selected patients</span><span class="headingEndMark"> — </span>In patients with abdominal pain as a major symptom, systemic symptoms (fever, weight loss), or suspected Crohn or pancreatic disease based on history, we perform additional abdominal imaging with an abdominal computed tomography (CT) or magnetic resonance imaging (MRI). In patients with suspected chronic pancreatitis, we perform a magnetic resonance cholangiopancreatography. An MRE (magnetic resonance enterography) can be used to identify small bowel Crohn disease or small bowel tumors. (See  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Imaging'</a>.)</p><p>Plain abdominal films have limited utility in the evaluation of chronic diarrhea. Supine and upright position can provide evidence of bowel distention or air-fluid levels suggesting a motility disease, megacolon due to infectious or inflammatory processes, or partial mechanical obstruction due to strictures in Crohn disease or tumors such as carcinoid. </p><p class="headingAnchor" id="H623430539"><span class="h2">Tests to evaluate uncommon causes</span><span class="headingEndMark"> — </span>Additional testing for uncommon disorders may be appropriate in the subset of patients with persistent symptoms in whom a diagnosis remains unclear  (<a class="graphic graphic_table graphicRef120912" href="/d/graphic/120912.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>We perform an upper endoscopy with mucosal biopsies, if not previously performed, to rule out small bowel enteropathies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We reserve laboratory testing for hormone secreting tumors (eg, fasting serum gastrin, calcitonin, somatostatin, vasoactive intestinal polypeptide, 24-hour urine 5-HIAA) in patients where no other etiology if found  (<a class="graphic graphic_algorithm graphicRef120910" href="/d/graphic/120910.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for laxatives may occasionally be required if laxative abuse is suspected based on history or endoscopic evaluation (presence of melanosis coli). A screen for laxative abuse should include the detection of anthraquinones, <a class="drug drug_general" data-topicid="8815" href="/d/drug information/8815.html" rel="external">bisacodyl</a> and phenolphthalein in urine and magnesium and phosphate in stool. (See  <a class="medical medical_review" href="/d/html/2628.html" rel="external">"Factitious diarrhea: Clinical manifestations, diagnosis, and management", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H2253927042"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H77636869"><span class="h2">Treatment of the underlying etiology</span><span class="headingEndMark"> — </span>Specific therapy should be directed to the underlying etiology in patients in whom the diagnosis has been established. The management of specific disorders associated with chronic diarrhea are presented in detail separately in the corresponding topic reviews.</p><p class="headingAnchor" id="H26"><span class="h2">Empiric therapy in selected patients</span><span class="headingEndMark"> — </span>Empiric therapy may be appropriate when comorbidities limit diagnostic evaluation or when a diagnosis is strongly suspected. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Empiric antibiotics for small intestinal bacterial overgrowth (SIBO) in patients with recurrent SIBO and predisposing risk factors. (See  <a class="medical medical_review" href="/d/html/4778.html" rel="external">"Small intestinal bacterial overgrowth: Management", section on 'Inadequate response to initial therapy or recurrence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lactose restriction in a patient with suspected lactose intolerance in whom relief of symptoms is observed following a temporary trial of a lactose-free diet. (See  <a class="medical medical_review" href="/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management", section on 'Dietary lactose restriction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">Cholestyramine</a> for bile acid diarrhea in a patient who develops diarrhea following limited (&lt;100 cm) ileal resection, abdominal radiation therapy, or post-cholecystectomy diarrhea [<a href="#rid16">16,22</a>]. It is reasonable to start patients on a low dose (eg, 2 g once or twice daily) and titrate to a higher dose as needed. We have found that patients often prefer pill formulations (ie, <a class="drug drug_general" data-topicid="9294" href="/d/drug information/9294.html" rel="external">colestipol</a>) over the powder (ie, cholestyramine). (See  <a class="medical medical_review" href="/d/html/4782.html" rel="external">"Overview of the treatment of malabsorption in adults", section on 'Directed therapy based on the underlying etiology'</a>.)</p><p></p><p class="headingAnchor" id="H27"><span class="h2">Symptomatic therapy</span><span class="headingEndMark"> — </span>Symptomatic therapy to reduce the frequency and severity of chronic diarrhea is indicated when the diagnosis has been made but definitive treatment is unavailable, when diagnosis has eluded diagnostic evaluation, and as a temporizing measure during evaluation. A variety of medications can help relieve diarrhea including <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>, anticholinergic agents, and intraluminal adsorbents (such as clays, activated charcoal, bismuth, fiber and bile acid binding resins). Symptomatic therapy may also be used to manage diarrhea in specific disorders and is discussed in the corresponding topic reviews. </p><p class="headingAnchor" id="H2905005393"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/127092.html" rel="external">"Society guideline links: Chronic diarrhea"</a>.)</p><p class="headingAnchor" id="H1740995085"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2000.html" rel="external">"Patient education: Chronic diarrhea in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology </strong>–<strong> </strong>Chronic diarrhea is defined as a persistent alteration of stool consistency from the norm with loose stools (consistency between types 5 and 7 on the Bristol stool chart) and increased stool frequency of greater than four weeks' duration. In resource-abundant settings the most prevalent causes are irritable bowel syndrome, inflammatory bowel disease (IBD), malabsorption syndromes (such as lactose intolerance and celiac disease), and chronic infections (particularly in patients who are immunocompromised)  (<a class="graphic graphic_table graphicRef120862" href="/d/graphic/120862.html" rel="external">table 1</a>). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for gastroenterology referral</strong> – The need for gastroenterology evaluation and timing of referral for chronic diarrhea depend upon the severity of symptoms, the diagnoses being considered, and the presence of alarm features  (<a class="graphic graphic_table graphicRef120912" href="/d/graphic/120912.html" rel="external">table 2</a>). (See <a class="local">'Indications for referral to a gastroenterologist'</a> above.)</p><p></p><p class="bulletIndent1">Indications for referral include anyone of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alarm features  (<a class="graphic graphic_table graphicRef120912" href="/d/graphic/120912.html" rel="external">table 2</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Severe diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Suspected inflammatory bowel disease (see <a class="local">'Inflammatory bowel disease'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Inconclusive diagnosis after initial evaluation (see <a class="local">'Initial evaluation'</a> above and <a class="local">'Establishing a diagnosis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Failure to respond to empiric therapy (see <a class="local">'Empiric therapy in selected patients'</a> above)</p><p></p><p class="bulletIndent1">Referral to a gastroenterologist may also be appropriate in patients who require long-term management for the underlying cause (eg, IBD, chronic pancreatitis). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation </strong>– The initial evaluation of patient with chronic diarrhea includes history, physical examination, and laboratory testing to determine whether the patient has any alarm features which help to distinguish organic from functional diarrhea and characterizing the diarrhea (infectious, inflammatory, osmotic, secretory) in order to direct evaluation  (<a class="graphic graphic_algorithm graphicRef120910" href="/d/graphic/120910.html" rel="external">algorithm 1</a>). (See <a class="local">'Overview'</a> above and <a class="local">'History'</a> above and <a class="local">'Physical examination'</a> above and <a class="local">'General laboratory tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation based on the presence of alarm features </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with alarm features</strong> – Patients with alarm features require endoscopic evaluation for organic disorders. Patients with abdominal pain as a major symptom in addition to chronic diarrhea often require abdominal imaging. (See <a class="local">'Endoscopic evaluation'</a> above and <a class="local">'Imaging in selected patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without alarm features</strong> – In patients without alarm features, if the initial evaluation points toward a specific diagnosis or type of diarrhea, further testing should be directed toward confirming the diagnosis. However, in some cases, further testing may be unnecessary (eg, functional diarrhea or suspected lactose intolerance) and patients can be managed empirically (lactose restriction for lactose intolerance, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> for post-cholecystectomy diarrhea). (See <a class="local">'Patients without alarm features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with persistent symptoms </strong>– In patients with persistent diarrhea with no clear etiology after initial evaluation or diarrhea that does not respond to initial treatment, we perform additional testing to determine the underlying etiology. This evaluation is individualized based on the clinical presentation and can include screening for evidence of malabsorption, stool tests for evidence of an infection, and endoscopic evaluation if not previously performed. We perform imaging (abdominal computed tomography or magnetic resonance imaging) in patients with unexplained diarrhea and abdominal pain as a major symptom, systemic symptoms (fever, weight loss), or suspected Crohn or pancreatic disease based on history. (See <a class="local">'Additional testing in specific circumstances'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed to earlier versions of this topic review and was a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Peery AF, Crockett SD, Murphy CC, et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology 2019; 156:254.</a></li><li><a class="nounderline abstract_t">Dutra B, Siddiqui S, Everett J. A Clinical Approach to Chronic Diarrhea. Gastroenterology 2022; 162:707.</a></li><li><a class="nounderline abstract_t">Arasaradnam RP, Brown S, Forbes A, et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut 2018; 67:1380.</a></li><li><a class="nounderline abstract_t">Schiller LR, Pardi DS, Spiller R, et al. Gastro 2013 APDW/WCOG Shanghai working party report: chronic diarrhea: definition, classification, diagnosis. J Gastroenterol Hepatol 2014; 29:6.</a></li><li><a class="nounderline abstract_t">Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2016; 44:693.</a></li><li><a class="nounderline abstract_t">Gómez-Escudero O, Remes-Troche JM. Approach to the adult patient with chronic diarrhea: A literature review. Rev Gastroenterol Mex (Engl Ed) 2021; 86:387.</a></li><li><a class="nounderline abstract_t">Gómez-Escudero O, Remes-Troche JM. Approach to the adult patient with chronic diarrhea: a literature review. Rev Gastroenterol Mex (Engl Ed) 2021.</a></li><li><a class="nounderline abstract_t">Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and Management. Clin Gastroenterol Hepatol 2017; 15:182.</a></li><li><a class="nounderline abstract_t">Singh P, Mitsuhashi S, Ballou S, et al. Demographic and Dietary Associations of Chronic Diarrhea in a Representative Sample of Adults in the United States. Am J Gastroenterol 2018; 113:593.</a></li><li><a class="nounderline abstract_t">Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 2009; 136:741.</a></li><li><a class="nounderline abstract_t">Peery AF, Crockett SD, Barritt AS, et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology 2015; 149:1731.</a></li><li><a class="nounderline abstract_t">Ma C, Congly SE, Novak KL, et al. Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis. Gastroenterology 2021; 160:88.</a></li><li><a class="nounderline abstract_t">Berumen A, Edwinson AL, Grover M. Post-infection Irritable Bowel Syndrome. Gastroenterol Clin North Am 2021; 50:445.</a></li><li><a class="nounderline abstract_t">Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil 2017; 23:151.</a></li><li><a class="nounderline abstract_t">Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021; 116:17.</a></li><li><a class="nounderline abstract_t">Costa S, Gattoni S, Nicolardi ML, et al. Prevalence and clinical features of bile acid diarrhea in patients with chronic diarrhea. J Dig Dis 2021; 22:108.</a></li><li><a class="nounderline abstract_t">Farrugia A, Attard JA, Hanmer S, et al. Rates of Bile Acid Diarrhoea After Cholecystectomy: A Multicentre Audit. World J Surg 2021; 45:2447.</a></li><li><a class="nounderline abstract_t">Camilleri M, Nurko S. Bile Acid Diarrhea in Adults and Adolescents. Neurogastroenterol Motil 2022; 34:e14287.</a></li><li><a class="nounderline abstract_t">Sauter GH, Moussavian AC, Meyer G, et al. Bowel habits and bile acid malabsorption in the months after cholecystectomy. Am J Gastroenterol 2002; 97:1732.</a></li><li><a class="nounderline abstract_t">Arlow FL, Dekovich AA, Priest RJ, Beher WT. Bile acid-mediated postcholecystectomy diarrhea. Arch Intern Med 1987; 147:1327.</a></li><li><a class="nounderline abstract_t">Breuer NF, Jaekel S, Dommes P, Goebell H. Fecal bile acid excretion pattern in cholecystectomized patients. Dig Dis Sci 1986; 31:953.</a></li><li><a class="nounderline abstract_t">Sadowski DC, Camilleri M, Chey WD, et al. Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. Clin Gastroenterol Hepatol 2020; 18:24.</a></li><li><a class="nounderline abstract_t">Schiller LR. Good News about BAD. Clin Gastroenterol Hepatol 2020; 18:45.</a></li><li><a class="nounderline abstract_t">Lo Vecchio A, Conelli ML, Guarino A. Infections and Chronic Diarrhea in Children. Pediatr Infect Dis J 2021; 40:e255.</a></li><li><a class="nounderline abstract_t">Bryant DA, Mintz ED, Puhr ND, et al. Colonic epithelial lymphocytosis associated with an epidemic of chronic diarrhea. Am J Surg Pathol 1996; 20:1102.</a></li><li><a class="nounderline abstract_t">Janda RC, Conklin JL, Mitros FA, Parsonnet J. Multifocal colitis associated with an epidemic of chronic diarrhea. Gastroenterology 1991; 100:458.</a></li><li><a class="nounderline abstract_t">Mintz ED, Weber JT, Guris D, et al. An outbreak of Brainerd diarrhea among travelers to the Galapagos Islands. J Infect Dis 1998; 177:1041.</a></li><li><a class="nounderline abstract_t">Osterholm MT, MacDonald KL, White KE, et al. An outbreak of a newly recognized chronic diarrhea syndrome associated with raw milk consumption. JAMA 1986; 256:484.</a></li><li><a class="nounderline abstract_t">Vugia DJ, Abbott S, Mintz ED, et al. A restaurant-associated outbreak of Brainerd diarrhea in California. Clin Infect Dis 2006; 43:62.</a></li><li><a class="nounderline abstract_t">Kimura AC, Mead P, Walsh B, et al. A large outbreak of Brainerd diarrhea associated with a restaurant in the Red River Valley, Texas. Clin Infect Dis 2006; 43:55.</a></li><li><a class="nounderline abstract_t">Hellmig S, Ott S, Musfeldt M, et al. Life-threatening chronic enteritis due to colonization of the small bowel with Stenotrophomonas maltophilia. Gastroenterology 2005; 129:706.</a></li><li><a class="nounderline abstract_t">Friedman M, Ramsay DB, Borum ML. An unusual case report of small bowel Candida overgrowth as a cause of diarrhea and review of the literature. Dig Dis Sci 2007; 52:679.</a></li><li><a class="nounderline abstract_t">Philip NA, Ahmed N, Pitchumoni CS. Spectrum of Drug-induced Chronic Diarrhea. J Clin Gastroenterol 2017; 51:111.</a></li><li><a class="nounderline abstract_t">Burbure N, Lebwohl B, Arguelles-Grande C, et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol 2016; 50:127.</a></li><li><a class="nounderline abstract_t">Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care 2017; 21:89.</a></li><li><a class="nounderline abstract_t">Mauloni PA, Capuani F, Paone C, et al. An unusual cause of diarrhoea: case report and literature review of olmesartan-associated enteropathy. Eur J Gastroenterol Hepatol 2021; 33:e1060.</a></li><li><a class="nounderline abstract_t">Sotiropoulos C, Sakka E, Diamantopoulou G, et al. Olmesartan-Induced Enteropathy: A Report of an Unusual Cause of Chronic Diarrhea. Cureus 2021; 13:e17004.</a></li><li><a class="nounderline abstract_t">Holtman GA, Lisman-van Leeuwen Y, Reitsma JB, Berger MY. Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Mosli MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2015; 110:802.</a></li><li><a class="nounderline abstract_t">Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003; 18:756.</a></li><li><a class="nounderline abstract_t">Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98:1309.</a></li><li><a class="nounderline abstract_t">Smalley W, Falck-Ytter C, Carrasco-Labra A, et al. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology 2019; 157:851.</a></li><li><a class="nounderline abstract_t">Schoepfer AM, Trummler M, Seeholzer P, et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007; 50:1697.</a></li><li><a class="nounderline abstract_t">Chitkara YK, McCasland KA, Kenefic L. Development and implementation of cost-effective guidelines in the laboratory investigation of diarrhea in a community hospital. Arch Intern Med 1996; 156:1445.</a></li><li><a class="nounderline abstract_t">Stoll BJ, Glass RI, Banu H, et al. Value of stool examination in patients with diarrhoea. Br Med J (Clin Res Ed) 1983; 286:2037.</a></li><li><a class="nounderline abstract_t">Siegel D, Cohen PT, Neighbor M, et al. Predictive value of stool examination in acute diarrhea. Arch Pathol Lab Med 1987; 111:715.</a></li><li><a class="nounderline abstract_t">Huicho L, Sanchez D, Contreras M, et al. Occult blood and fecal leukocytes as screening tests in childhood infectious diarrhea: an old problem revisited. Pediatr Infect Dis J 1993; 12:474.</a></li><li><a class="nounderline abstract_t">Ferren LG, Ward RL, Campbell BJ. Monoanion inhibition and 35Cl nuclear magnetic resonance studies of renal dipeptidase. Biochemistry 1975; 14:5280.</a></li><li><a class="nounderline abstract_t">Hodgson EK, Fridovich I. The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: inactivation of the enzyme. Biochemistry 1975; 14:5294.</a></li><li><a class="nounderline abstract_t">Jaton JC, Huser H, Blatt Y, Pecht I. Circular dichroism and fluorescence studies of homogeneous antibodies to type III pneumococcal polysaccharide. Biochemistry 1975; 14:5308.</a></li><li><a class="nounderline abstract_t">Jaton JC, Huser H, Braun DG, et al. Conformational changes induced in a homogeneous anti-type III pneumococcal antibody by oligosaccharides of increasing size. Biochemistry 1975; 14:5312.</a></li></ol></div><div id="topicVersionRevision">Topic 2591 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30315778" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34331913" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A Clinical Approach to Chronic Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29653941" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24117999" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gastro 2013 APDW/WCOG Shanghai working party report: chronic diarrhea: definition, classification, diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27492648" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34389290" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Approach to the adult patient with chronic diarrhea: A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34074557" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Approach to the adult patient with chronic diarrhea: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27496381" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic Diarrhea: Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610515" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Demographic and Dietary Associations of Chronic Diarrhea in a Representative Sample of Adults in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19166855" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Burden of digestive diseases in the United States part II: lower gastrointestinal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26327134" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33010247" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34024451" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Post-infection Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28274109" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : What Is New in Rome IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33315591" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ACG Clinical Guideline: Management of Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33438795" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence and clinical features of bile acid diarrhea in patients with chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33982189" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rates of Bile Acid Diarrhoea After Cholecystectomy: A Multicentre Audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34751982" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bile Acid Diarrhea in Adults and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12135027" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bowel habits and bile acid malabsorption in the months after cholecystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3606289" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bile acid-mediated postcholecystectomy diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3731987" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fecal bile acid excretion pattern in cholecystectomized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31526844" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31676357" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Good News about BAD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34097662" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Infections and Chronic Diarrhea in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8764747" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Colonic epithelial lymphocytosis associated with an epidemic of chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985042" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Multifocal colitis associated with an epidemic of chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9534980" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An outbreak of Brainerd diarrhea among travelers to the Galapagos Islands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3487659" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An outbreak of a newly recognized chronic diarrhea syndrome associated with raw milk consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16758419" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A restaurant-associated outbreak of Brainerd diarrhea in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16758418" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A large outbreak of Brainerd diarrhea associated with a restaurant in the Red River Valley, Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083723" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Life-threatening chronic enteritis due to colonization of the small bowel with Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277989" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : An unusual case report of small bowel Candida overgrowth as a cause of diarrhea and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027072" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Spectrum of Drug-induced Chronic Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26997446" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28407743" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34334714" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : An unusual cause of diarrhoea: case report and literature review of olmesartan-associated enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34540405" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Olmesartan-Induced Enteropathy: A Report of an Unusual Cause of Chronic Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26681783" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964225" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12795745" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Emerging role of calprotectin in gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12818275" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31302098" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762964" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Accuracy of four fecal assays in the diagnosis of colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678713" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Development and implementation of cost-effective guidelines in the laboratory investigation of diarrhea in a community hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6307460" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Value of stool examination in patients with diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3632285" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Predictive value of stool examination in acute diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345979" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Occult blood and fecal leukocytes as screening tests in childhood infectious diarrhea: an old problem revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/48" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Monoanion inhibition and 35Cl nuclear magnetic resonance studies of renal dipeptidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/49" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: inactivation of the enzyme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/50" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Circular dichroism and fluorescence studies of homogeneous antibodies to type III pneumococcal polysaccharide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/51" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Conformational changes induced in a homogeneous anti-type III pneumococcal antibody by oligosaccharides of increasing size.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
